Hospital
University of South Alabama
University of South Alabama was paid $24.82M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 23% of everything it billed.
33Billing provider infoUNIVERSITY OF SOUTH ALABAMA
MOBILE, AL 36604
MOBILE, AL 36604
33aNPI1023055191assigned 05/31/2006
33bProvider typeWomen's Hospital
28Total paid$24.82M
24GClaims671,292
24DCodes billed169
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,696 | $1.47M | |
| 2019 | 65,035 | $1.86M | |
| 2020 | 50,552 | $1.35M | |
| 2021 | 148,410 | $4.68M | |
| 2022 | 141,531 | $5.31M | |
| 2023 | 123,390 | $5.81M | |
| 2024incomplete | 92,678 | $4.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23% | 114,412 | 99,279 | $5.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 116,756 | 109,317 | $5.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 40,958 | 38,832 | $3.43M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 8.7% | 44,713 | 42,705 | $2.17M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.2% | 32,379 | 30,996 | $2.02M |
| 87634 | 3.7% | 16,713 | 16,028 | $920K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 17,810 | 16,589 | $728K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 1,022 | 975 | $361K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 37,362 | 29,158 | $333K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.2% | 6,495 | 4,629 | $291K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.2% | 2,002 | 976 | $286K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.0% | 6,391 | 6,180 | $249K |
157 more codes
| 80053 | Comprehensive metabolic panel | <1% | 22,645 | $238K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 597 | $235K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,663 | $208K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 671 | $180K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,821 | $173K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,257 | $148K |
| 81001 | <1% | 34,016 | $147K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 828 | $120K |
| 93325 | <1% | 2,318 | $117K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,258 | $112K |
| 87088 | <1% | 8,759 | $105K | |
| G0378 | Hospital observation service, per hour | <1% | 276 | $101K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,783 | $98K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,084 | $86K |
| 81002 | <1% | 21,537 | $83K | |
| 87400 | <1% | 8,046 | $82K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,303 | $81K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,188 | $69K |
| 76820 | <1% | 1,479 | $66K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,629 | $65K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 276 | $64K |
| 81025 | <1% | 18,056 | $58K | |
| 93321 | <1% | 1,386 | $56K | |
| 87420 | <1% | 3,815 | $54K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,584 | $40K |
| 93304 | <1% | 763 | $36K | |
| 87430 | <1% | 2,181 | $32K | |
| 76825 | <1% | 301 | $28K | |
| 90686 | <1% | 2,760 | $27K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 970 | $25K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 855 | $24K |
| 76830 | Ultrasound, transvaginal | <1% | 737 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,036 | $21K |
| 76770 | <1% | 352 | $19K | |
| 84702 | <1% | 1,457 | $17K | |
| 86300 | <1% | 1,045 | $15K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 12 | $14K |
| 86850 | <1% | 2,267 | $13K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 461 | $12K |
| 82947 | <1% | 2,368 | $12K | |
| 45331 | <1% | 121 | $12K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 486 | $11K |
| 87081 | <1% | 1,028 | $10K | |
| 85046 | <1% | 1,726 | $9K | |
| 16020 | <1% | 29 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 726 | $8K |
| 74018 | <1% | 694 | $8K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,262 | $7K |
| 86900 | <1% | 2,286 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 402 | $7K |
| 86140 | <1% | 2,933 | $7K | |
| 86901 | <1% | 2,289 | $6K | |
| 92523 | <1% | 62 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 152 | $6K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 196 | $5K |
| 81003 | <1% | 1,083 | $4K | |
| 54161 | <1% | 13 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 55 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 164 | $4K |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | <1% | 19 | $3K |
| 85027 | <1% | 442 | $3K | |
| 76775 | <1% | 129 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $2K |
| 76801 | <1% | 87 | $2K | |
| 85045 | <1% | 422 | $2K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 26 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 376 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 103 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 133 | $2K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 180 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 92 | $2K |
| 87807 | <1% | 149 | $2K | |
| 93320 | <1% | 26 | $2K | |
| 87040 | <1% | 160 | $2K | |
| 90715 | <1% | 62 | $1K | |
| 82272 | <1% | 420 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 75 | $1K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,688 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 31 | $1K |
| 88142 | <1% | 34 | $979.83 | |
| 93271 | <1% | 13 | $944.71 | |
| 87077 | <1% | 117 | $942.90 | |
| 82728 | <1% | 84 | $797.37 | |
| 96402 | <1% | 56 | $782.00 | |
| 81015 | <1% | 252 | $657.51 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,396 | $649.18 |
| 92551 | <1% | 35 | $580.93 | |
| 82247 | <1% | 250 | $507.80 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 226 | $458.56 |
| 71045 | Radiologic examination, chest; single view | <1% | 69 | $436.92 |
| 82951 | <1% | 49 | $413.69 | |
| 82784 | <1% | 31 | $397.30 | |
| 94060 | <1% | 15 | $373.66 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 204 | $371.80 |
| 83690 | <1% | 53 | $371.68 | |
| 82150 | <1% | 53 | $371.22 | |
| 83615 | <1% | 76 | $369.60 | |
| 82952 | <1% | 48 | $352.50 | |
| 70360 | <1% | 32 | $341.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $337.08 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $299.16 |
| 84439 | <1% | 41 | $252.25 | |
| 87186 | <1% | 29 | $212.31 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13 | $208.52 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 69 | $192.60 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 395 | $191.05 |
| 73130 | <1% | 13 | $153.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 157 | $137.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,647 | $98.73 |
| 83735 | <1% | 19 | $96.14 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,499 | $92.10 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 198 | $88.35 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 416 | $69.03 |
| 36416 | <1% | 68 | $68.02 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 94 | $65.50 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 580 | $45.87 |
| 99406 | <1% | 19 | $25.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 340 | $19.25 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $12.43 |
| 90633 | 0% | 888 | $0.00 | |
| 99177 | 0% | 3,413 | $0.00 | |
| 90670 | 0% | 4,863 | $0.00 | |
| 90710 | 0% | 291 | $0.00 | |
| 90648 | 0% | 2,465 | $0.00 | |
| 99173 | 0% | 462 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 85 | $0.00 |
| 92202 | 0% | 639 | $0.00 | |
| 96160 | 0% | 309 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 96 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 275 | $0.00 |
| 90734 | 0% | 27 | $0.00 | |
| 92201 | 0% | 140 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 13 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 52 | $0.00 |
| 90700 | 0% | 12 | $0.00 | |
| 90707 | 0% | 14 | $0.00 | |
| 90680 | 0% | 2,091 | $0.00 | |
| 90723 | 0% | 1,210 | $0.00 | |
| 90744 | 0% | 122 | $0.00 | |
| 94760 | 0% | 130 | $0.00 | |
| 96127 | 0% | 1,727 | $0.00 | |
| 96161 | 0% | 119 | $0.00 | |
| 90698 | 0% | 535 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 43 | $0.00 |
| 82962 | 0% | 70 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 34 | $0.00 |
| 90656 | 0% | 16 | $0.00 | |
| 90651 | 0% | 33 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 84 | $0.00 |
| 90696 | 0% | 13 | $0.00 | |
| 93270 | 0% | 13 | $0.00 | |
| 88304 | 0% | 13 | $0.00 | |
| 93788 | 0% | 12 | $0.00 | |
| 90716 | 0% | 14 | $0.00 | |
| 95012 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBERTS, KRISTEN (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| University of South Alabama | Mobile, AL | $4.62M |
| University of South Alabama | Mobile, AL | $4.61M |
| USA Health Anesthesia Billing Services, LLC | Mobile, AL | $1.91M |
| USA Health Hca Providence Hospital LLC | Mobile, AL | $357K |
| Childhood Educational Associates, LLC | Schenectady, NY | $68K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.